AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

HIV Vaccine

Using Pre-Exposure Prophylaxis (PrEP) as a Prevention Tool for MSM: The Promise Comes with Challenges

Ronald Valdiserri

On Saturday, February 26th, I attended a day-long meeting organized by the Centers for Disease Control and Prevention (CDC) and hosted by the Fenway Community Health Center in Boston. The theme of the meeting was “Moving forward with PrEP Implementation.” Meeting participants included researchers involved in the original iPrEX study and other ongoing HIV prevention…

President Obama Welcomes New HIV Prevention Research Results

blog.aids.gov

WASHINGTON, D.C. – Today, the National Institutes of Health announced findings on recent HIV prevention research.  The study finds that a daily dose of an oral antiretroviral drug taken by HIV-negative gay and bisexual men reduced the risk of acquiring HIV infection by 43.8 percent, and had even higher rates of effectiveness, up to 73…

NIH-Led Scientists Find Antibodies that Prevent Most HIV Strains from Infecting Human Cells

blog.aids.gov

Scientists have discovered two potent human antibodies that can stop more than 90 percent of known global HIV strains from infecting human cells in the laboratory. The scientists also have demonstrated how one of these disease-fighting proteins accomplishes this feat. According to the scientists, these antibodies could be used to design improved HIV vaccines, or…

International AIDS Conference Day 3: Research Highlights

Dr. Ron Valdiserri

Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, shared the latest scientific information with the conference delegates about the actual steps that the human immunodeficiency virus (HIV) takes when it makes contact with the human genital tract (through exposure to semen or vaginal secretions) which result in infection.Understanding, in detail,…

Renewed Hope for an HIV Vaccine

Dr. Carl Dieffenbach, PhD

In late September, the U.S. federal government announced news on HIV vaccine research that sparked interest around the world. A trial called RV144, or the Thai HIV vaccine clinical trial , showed that the experimental vaccine regimen was safe and about 31 percent effective in preventing HIV infection. Although the vaccine regimen had a very…

HIV Vaccine Regimen Demonstrates Modest Preventive Effect in Thailand Clinical Study

blog.aids.gov

In an encouraging development, an investigational vaccine regimen has been shown to be well-tolerated and to have a modest effect in preventing HIV infection in a clinical trial involving more than 16,000 adult participants in Thailand. Following a final analysis of the trial data, the Surgeon General of the U.S. Army, the trial sponsor, announced…

Page 2 of 212